/Companies

Whitehawk

8 known investors

Find your way into Whitehawk

Sign up to see every warm intro you have to Whitehawk

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Whitehawk team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Whitehawk Therapeutics develops antibody-drug conjugate (ADC) therapeutics through intentional clinical development. The company brings expertise in biotech R&D and commercialization to treat patients using its ADC platform.

Founders & leadership

DLDave Lennon, PhD
Dave Lennon, PhDPresident & CEO
DLDave Lennon
Dave LennonPresident & CEOPresident and CEO of Whitehawk Therapeutics, which develops antibody-drug conjugate therapeutics for treating patients.

Investors · 8

Also in the syndicate · 6

Acuta Capital PartnersADAR1 Capital ManagementCoastlands CapitalKVP CapitalQVTStemPoint Capital LP

Funding

SEC filings, press & company announcements
  • Undisclosed amountprivate placementMay 2026

    Acuta Capital Partners, ADAR1 Capital Management, Avoro Capital, Coastlands Capital, Invus, KVP Capital, QVT, StemPoint Capital LP

    Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Frequently asked questions

What does Whitehawk do?
Whitehawk Therapeutics develops antibody-drug conjugate (ADC) therapeutics through intentional clinical development. The company brings expertise in biotech R&D and commercialization to treat patients using its ADC platform.
Who are Whitehawk's investors?
Whitehawk's investors include Avoro Capital Advisors, Invus.